NanoRepro AG (NN6) - Total Assets
Based on the latest financial reports, NanoRepro AG (NN6) holds total assets worth €37.99 Million EUR (≈ $44.42 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NanoRepro AG shareholders equity for net asset value and shareholders' equity analysis.
NanoRepro AG - Total Assets Trend (2008–2024)
This chart illustrates how NanoRepro AG's total assets have evolved over time, based on quarterly financial data.
NanoRepro AG - Asset Composition Analysis
Current Asset Composition (December 2024)
NanoRepro AG's total assets of €37.99 Million consist of 38.3% current assets and 61.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €9.10 Million | 23.3% |
| Accounts Receivable | €545.83K | 1.4% |
| Inventory | €901.40K | 2.3% |
| Property, Plant & Equipment | €347.36K | 0.9% |
| Intangible Assets | €3.36 Million | 8.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how NanoRepro AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NN6 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NanoRepro AG's current assets represent 38.3% of total assets in 2024, a decrease from 66.0% in 2008.
- Cash Position: Cash and equivalents constituted 23.3% of total assets in 2024, down from 39.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is cash and equivalents at 23.3% of total assets.
NanoRepro AG Competitors by Total Assets
Key competitors of NanoRepro AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.22 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.43 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$1.33 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
NanoRepro AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 32.12 | 74.25 | 12.02 |
| Quick Ratio | 30.64 | 72.16 | 7.77 |
| Cash Ratio | 23.20 | 56.85 | 5.49 |
| Working Capital | €9.78 Million | €30.65 Million | €4.05 Million |
NanoRepro AG - Advanced Valuation Insights
This section examines the relationship between NanoRepro AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.52 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | €39.03 Million |
| Market Capitalization | $18.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values NanoRepro AG's assets below their book value (0.48x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: NanoRepro AG's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NanoRepro AG (2008–2024)
The table below shows the annual total assets of NanoRepro AG from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €39.03 Million ≈ $45.62 Million |
-5.87% |
| 2023-12-31 | €41.46 Million ≈ $48.47 Million |
-16.20% |
| 2022-12-31 | €49.48 Million ≈ $57.84 Million |
-37.49% |
| 2021-12-31 | €79.15 Million ≈ $92.53 Million |
+608.58% |
| 2020-12-31 | €11.17 Million ≈ $13.06 Million |
+132.55% |
| 2019-12-31 | €4.80 Million ≈ $5.62 Million |
-17.27% |
| 2018-12-31 | €5.81 Million ≈ $6.79 Million |
+38.32% |
| 2017-12-31 | €4.20 Million ≈ $4.91 Million |
+19.47% |
| 2016-12-31 | €3.51 Million ≈ $4.11 Million |
+44.06% |
| 2015-12-31 | €2.44 Million ≈ $2.85 Million |
+12.28% |
| 2014-12-31 | €2.17 Million ≈ $2.54 Million |
+21.67% |
| 2013-12-31 | €1.79 Million ≈ $2.09 Million |
+68.32% |
| 2012-12-31 | €1.06 Million ≈ $1.24 Million |
+6.26% |
| 2011-12-31 | €998.11K ≈ $1.17 Million |
-48.61% |
| 2010-12-31 | €1.94 Million ≈ $2.27 Million |
+331.70% |
| 2009-12-31 | €449.94K ≈ $526.03K |
+3.65% |
| 2008-12-31 | €434.09K ≈ $507.50K |
-- |
About NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more